Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.48 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28701397 | 0.82 | KDM4E (0.53) | KDM4EL3MBTL1MPIMAPTSMN1; SMN2 | |
| SCHEMBL3566110 | 0.81 | MAPT (0.62) | KDM4EL3MBTL1MPIMAPTSMN1; SMN2 | |
| SCHEMBL14095081 | 0.80 | HTR1A (0.54) | KDM4EL3MBTL1MPIMAPTSMN1; SMN2 | |
| SCHEMBL13437112 | 0.78 | KDM4E (0.48) | KDM4EL3MBTL1MPIMAPTSMN1; SMN2 | |
| SCHEMBL3561305 | 0.77 | HTR2A (0.44) | KDM4EL3MBTL1MAPTSMN1; SMN2TNNI3 | |
| SCHEMBL3565769 | 0.76 | HTR2A (0.65) | L3MBTL1ALDH1A1HTR1ALMNAKMT2A | |
| SCHEMBL3558707 | 0.74 | HTR1A (0.47) | KDM4EL3MBTL1MPIMAPTSMN1; SMN2 | |
| SCHEMBL2844754 | 0.72 | LMNA (0.59) | L3MBTL1MAPTALDH1A1MAPK1LMNA | |
| SCHEMBL7957352 | 0.72 | ADRB2 (0.51) | KDM4EMAPTSMN1; SMN2ALDH1A1HTR1A | |
| SCHEMBL3556376 | 0.71 | HTR1A (0.73) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2008067390-A9 | METABOLITES OF 5-FLUORO-8-{4-[4-(6-METHOXYQUINOLIN-8-YL)PIPERAZIN-1-YL]PIPERIDIN-1-YL} QUINOLINE AND METHODS OF PREPARATION AND USES THEREOF | WYETH CORP (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008067390-A9 | METABOLITES OF 5-FLUORO-8-{4-[4-(6-METHOXYQUINOLIN-8-YL)PIPERAZIN-1-YL]PIPERIDIN-1-YL} QUINOLINE AND METHODS OF PREPARATION AND USES THEREOF | WYETH CORP (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-2035384-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2029577-A2 | CRYSTALLINE FORMS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2027112-A2 | SUCCINATE SALTS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE AND CRYSTALLINE FORMS THEREOF | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027111-A2 | 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE HYDROCHLORIC ACID SALTS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080262228-A1 | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070299083-A1 | 6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007146116-A2 | CRYSTALLINE FORMS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146115-A2 | 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE HYDROCHLORIC ACID SALTS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146072-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146202-A2 | SUCCINATE SALTS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299083-A1 | 6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | HTR5A, HTR2C, HTR1A | KDM4E 3120/4885L3MBTL1 4858/4885MPI 1815/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | KDM4E 907/4885L3MBTL1 4495/4885MPI 3230/4885 |
| US-20080262228-A1 | Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof | UGT1A8, CYP2C8, NQO1 | KDM4E 1201/4885L3MBTL1 4423/4885MPI 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.